# Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

> **NCT04496674** · PHASE1,PHASE2 · TERMINATED · sponsor: **German Cancer Research Center** · enrollment: 3 (actual)

## Conditions studied

- Lung Cancer Squamous Cell

## Interventions

- **DRUG:** CC-1 and Toczilizumab

## Key facts

- **NCT ID:** NCT04496674
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-02
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** premature termination of the trial due to bad recruitment
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04496674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04496674, "Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04496674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*